Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 4
2004 4
2005 6
2006 5
2007 9
2008 12
2009 10
2010 12
2011 14
2012 15
2013 12
2014 22
2015 28
2016 39
2017 30
2018 22
2019 32
2020 27
2021 33
2022 25
2023 22
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: magne n. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP, Barbet N, Schiappa R, Magné N, Martel I, Mineur L, Deberne M, Zilli T, Dhadda A, Myint AS; ICONE group. Gerard JP, et al. Among authors: magne n. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):356-367. doi: 10.1016/S2468-1253(22)00392-2. Epub 2023 Feb 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36801007 Clinical Trial.
Cancer du rein et radiothérapie : radiorésistance et au-delà.
Mery B, Rancoule C, Rowinski E, Bosacki C, Vallard A, Guy JB, Magné N. Mery B, et al. Among authors: magne n. Bull Cancer. 2018 Dec;105 Suppl 3:S280-S285. doi: 10.1016/S0007-4551(18)30383-7. Bull Cancer. 2018. PMID: 30595157 Review. French.
Radiothérapie et immunothérapie.
Rancoule C, Vallard A, Jmour O, Vial N, Guillaume E, Guy JB, Magné N. Rancoule C, et al. Among authors: magne n. Bull Cancer. 2018 Dec;105 Suppl 1:S92-S100. doi: 10.1016/S0007-4551(18)30394-1. Bull Cancer. 2018. PMID: 30595203 Review. French.
Cancer du rein : tendances et perspectives.
Mery B, Thiery-Vuillemin A, Massard C, Albiges L, Magné N. Mery B, et al. Among authors: magne n. Bull Cancer. 2018 Dec;105 Suppl 3:S219-S220. doi: 10.1016/S0007-4551(18)30375-8. Bull Cancer. 2018. PMID: 30595149 French.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Tao Y, et al. Among authors: magne n. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36796234 Free article. Clinical Trial.
Brachytherapy and fertility.
Falk AT, Chargari C, Hannoun-Lévi JM, Adrados C, Antomarchi J, Guy JB, Mazeron R, Haie-Meder C, Magné N. Falk AT, et al. Among authors: magne n. Hum Fertil (Camb). 2016 Jun;19(2):85-9. doi: 10.1080/14647273.2016.1190466. Epub 2016 Jun 16. Hum Fertil (Camb). 2016. PMID: 27308857 Review.
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Morvan C, Campion L, Blanc-Lapierre A. Supiot S, et al. Among authors: magne n. Eur Urol. 2021 Oct;80(4):405-414. doi: 10.1016/j.eururo.2021.06.010. Epub 2021 Jul 8. Eur Urol. 2021. PMID: 34247896 Clinical Trial.
342 results